Form 4: Tenaya Therapeutics Director Granted Over 100,000 Stock Options

Catherine Stehman-Breen, a Director at Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444 per share.

Summary

• Catherine Stehman-Breen, a Director of Tenaya Therapeutics, Inc. (TNYA), acquired 107,400 stock options on May 29, 2025.
• The stock options have an exercise price of $0.4444 per share.
• These options were granted under the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.
• The options will vest in full on May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date.
• Vesting is contingent upon Ms. Stehman-Breen continuing to be a service provider to the Issuer through each applicable vesting date.
• The expiration date for these options is May 28, 2035.
• Following this transaction, Ms. Stehman-Breen beneficially owns 107,400 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally neutral but can be seen as slightly positive due to the alignment of director and shareholder interests.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The transaction is a routine equity compensation event under an established company plan (2021 Equity Incentive Plan), indicating standard corporate governance practices.

Future Outlook

The vesting schedule of the stock options, extending to May 29, 2026, or earlier, implies an expectation of continued service from the director to Tenaya Therapeutics, Inc.

Management Comments

• The option was granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.
• Vesting is subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation for directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The structure, including vesting schedules and exercise prices, is typical for incentive-based compensation plans designed to align director performance with company success over several years.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options represents a potential future dilution if exercised, but also serves to align the director's incentives with shareholder value creation.
• Employees (specifically the director): Provides a significant equity incentive tied to the company's future performance and continued service.

Next Steps

• The stock options will vest in full on May 29, 2026, or earlier, subject to continued service.
• The director may choose to exercise the options at any time after vesting and before the expiration date of May 28, 2035.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Stock Option, Director Compensation, Insider Transaction, Equity Incentive Plan, Form 4, Beneficial Ownership